Anika Therapeutics (NASDAQ:ANIK) reported Q2 EPS of ($0.12), $0.11 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $39.7 million versus the consensus estimate of $37.85 million.
Anika Therapeutics (NASDAQ:ANIK) reported Q2 EPS of ($0.12), $0.11 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $39.7 million versus the consensus estimate of $37.85 million.